U.S. Communications Stock News

If you are wondering whether Omnicell's current share price really reflects its potential, this article will walk through how the stock stacks up on value. The shares most recently closed at US$36.18, after returns of a 7.4% decline over 7 days, 29.6% decline over 30 days, 19.8% decline year to date, 10.1% decline over 1 year, 33.5% decline over 3 years, and 72.1% decline over 5 years. Recent news coverage around Omnicell has focused on the company as part of broader discussions about...

Confluent (CFLT) just wrapped up FY 2025 with Q4 revenue of US$314.8 million and a basic EPS loss of US$0.23, while trailing twelve month revenue sat at about US$1.17 billion against a full year basic EPS loss of US$0.86. Over recent quarters, the company has seen revenue move from US$261.2 million in Q4 2024 to US$314.8 million in Q4 2025, with quarterly basic EPS losses ranging between US$0.19 and US$0.27. The latest print keeps the spotlight firmly on how quickly revenue growth can offset...

If you are wondering whether PennyMac Mortgage Investment Trust is offering good value at its recent share price, you are not alone. This article is designed to help you make sense of that question. The stock most recently closed at US$12.49, with returns of 2.0% over the past week, a 5.2% decline over the past month, a 1.3% decline year to date, and a 3.4% return over the last year, alongside cumulative returns of 26.2% over three years and 22.1% over five years. Recent coverage has focused...

Sarepta Therapeutics (NasdaqGS:SRPT) received Medsafe approval in New Zealand for its first-in-human clinical trial of SRP-1005. SRP-1005 is an investigational siRNA therapeutic targeting Huntington's Disease, a severe neurodegenerative condition. The authorization allows Sarepta to begin a Phase 1 study, marking its clinical entry into Huntington's Disease research. Sarepta Therapeutics is best known for its Duchenne muscular dystrophy franchise, and SRP-1005 broadens its rare disease...

Core Natural Resources (CNR) has posted a mixed set of FY 2025 numbers, with Q3 revenue at about US$1.0 billion and basic EPS of US$0.61 alongside a trailing twelve month loss of US$43.4 million on basic EPS of US$0.94. The company has seen quarterly revenue move from US$553.4 million in Q3 2024 to more than US$1.0 billion in Q3 2025, while basic EPS has swung between a profit of US$3.23 and a loss of US$1.38 over that stretch. This highlights how volatile margins have been. For investors,...

If you are wondering whether Easterly Government Properties is fairly priced or offering value right now, this article will walk you through what the numbers actually say. The stock last closed at US$23.79, with a 30 day return of 6.3% and an 11.6% return year to date, set against a 3.1% decline over the past year and a 23.7% and 37.1% decline over the past 3 and 5 years respectively. Recent coverage of Easterly Government Properties has focused on its position as a real estate investment...

What is moving Amphastar Pharmaceuticals now? Amphastar Pharmaceuticals (AMPH) has drawn investor attention after its recent share performance, with the stock around $27.55 and short term returns mixed between the past week, month and past 3 months. See our latest analysis for Amphastar Pharmaceuticals. At around $27.55, Amphastar Pharmaceuticals has given investors a mixed ride, with recent share price returns over the past week and month soft, while the 90 day share price return of 5.72%...

If you are wondering whether Tencent Music Entertainment Group's current share price reflects its true worth, you are not alone. This article is built to help you make sense of the numbers. The stock closed at US$15.15, with returns of a 4.9% decline over the last 7 days, a 13.8% decline over 30 days, a 15.2% decline year to date, a 20.2% gain over 1 year, an 87.1% gain over 3 years, and a 42.3% decline over 5 years. Recent moves therefore sit within a mixed longer term picture. Recent...

If you are wondering whether Kodiak AI at around US$8.35 is starting to look interesting on price alone, it helps to step back and look at what the current market is implying about its value. Over the short term, the stock has been under pressure, with a 7 day return of 4.4% decline, a 30 day return of 11.1% decline, and a year to date return of 22.9% decline, contributing to a 24.4% decline over the past year. This weaker share price backdrop is unfolding alongside broader evergreen...

In early February 2026, PotlatchDeltic Corporation was removed from the NASDAQ Composite Index, while multiple long-running ESOP-related shelf registrations for common stock were formally closed. This combination highlights how a technical index change, rather than routine employee stock plan administration, can have an outsized influence on trading flows and investor attention. Next, we’ll examine how PotlatchDeltic’s removal from the NASDAQ Composite Index could affect its existing...

FirstEnergy (NYSE:FE) announced a 4.5% increase to its quarterly dividend. The company also provided forward dividend guidance, outlining expectations for higher annual payouts. Management linked the dividend update to confidence in the company’s ongoing transformation and operations. For income focused investors watching utilities, this dividend move from FirstEnergy comes on top of a solid share price run. NYSE:FE is trading at $48.84, with the stock up 3.9% over the past week and 7.8%...

If you are wondering whether Tower Semiconductor is still priced reasonably after its strong run, or if you might be looking at a stretched stock, this article walks through what the current share price could mean for you. The stock last closed at US$133.58, with returns of 3.5% over 7 days, 7.1% over 30 days, 9.7% year to date, 177.1% over 1 year and 321.5% over 5 years. This naturally raises questions about what is already baked into the price. Recent news flow around Tower Semiconductor...

IDEX Corporation recently reported fourth-quarter 2025 results showing higher sales of US$899.1 million and net income of US$128.3 million, while also continuing its long-running share repurchase program. Soon after these results, IDEX moved to eliminate the role of Senior Vice President, Chief Strategy and Innovation Officer Roopa Unnikrishnan, signaling an organizational shift in how it approaches growth and innovation. We’ll now consider how the stronger quarter, especially momentum in...

G-III Apparel Group recently advanced the revival of DKNY and Donna Karan New York by extending Hailey Bieber’s global ambassador role for DKNY and launching Spring 2026 campaigns featuring Adriana Lima, Joan Smalls, and Grace Elizabeth across key retail and digital channels. By pairing high-impact celebrity campaigns with curated edits that emphasize each model’s personal expression, the company is sharpening the distinct identities of its owned brands and potentially strengthening consumer...

If you are wondering whether Futu Holdings at around US$147.48 is still good value or starting to look stretched, you are not alone. The stock has seen a 1.7% decline over the last 7 days and a 19.9% decline over the last 30 days, even though the 1 year return sits at 25.1% and the 3 year return is a very large 201.3%. Recent news coverage has focused on Futu Holdings as a key online broker for Chinese equities and global markets, with attention on how investor trading activity and...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Travel + Leisure fair value estimate is US$100 Current share...

Some Ameriprise Financial, Inc. ( NYSE:AMP ) shareholders may be a little concerned to see that the Chairman & CEO...

Estée Lauder Companies (NYSE:EL) has filed a federal lawsuit against Walmart, alleging the retailer sold counterfeit skincare and fragrance products online. The suit targets products tied to brands including Aveda, Clinique, La Mer, Le Labo, and Tom Ford. Estée Lauder is seeking an injunction and monetary damages in response to the alleged counterfeit sales. For investors watching NYSE:EL, this legal move comes with the stock at a share price of $106.42. The company’s recent performance has...

First American Financial (FAF) just wrapped up FY 2025 with Q4 revenue of US$2.0 billion and basic EPS of US$2.06, supported by trailing 12 month revenue of US$7.5 billion and EPS of US$6.02. Over recent quarters, the company has seen revenue move from US$1.6 billion and EPS of US$0.71 in Q1 2025 to US$2.0 billion and EPS of US$2.06 in Q4 2025, while trailing net profit margin sits at 8.3% compared with 2.1% a year earlier. This points to a period where profitability has become a much bigger...

Sylvamo (SLVM) just posted its FY 2025 third quarter numbers, reporting revenue of US$846 million and basic EPS of US$1.43 alongside net income of US$57 million. The company’s quarterly revenue moved from US$970 million in Q4 2024 to US$821 million in Q1 2025, US$794 million in Q2, and then US$846 million in Q3. Over the same period, basic EPS went from US$1.98 to US$0.67, US$0.37, and then US$1.43. These shifts give investors more detail for evaluating how recent performance trends relate to...

In early February 2026, McCune Law Group filed a wrongful death lawsuit against Abbott Diabetes Care and Abbott Laboratories over alleged accuracy defects in FreeStyle Libre 3 glucose sensors, following prior Class I safety actions and an FDA-classified serious device concern affecting about 3 million sensors. At the same time, Abbott has been highlighting strong clinical results across its cardiac device portfolio and raising its dividend, underscoring the tension between product...

Tenet Healthcare (NYSE:THC) has completed a transaction with CommonSpirit Health involving its Conifer Health Solutions subsidiary. The deal reshapes Tenet's relationship with Conifer, a key provider of revenue cycle management and related services to health systems. Investors are watching for implications for Tenet's business mix, capital allocation, and long term operating focus. For you as an investor, this matters because Conifer sits at the intersection of hospital operations and...

Hartford Insurance Group (NYSE:HIG) is integrating its benefits offerings with Centro Benefits Research's digital broker carrier platform. The move aligns with findings from Hartford's Future of Benefits Study on employer demand for simpler, tech driven benefits solutions. The collaboration focuses on streamlining how brokers and employers access and manage Hartford's employee benefits products. For investors watching NYSE:HIG, the integration with Centro Benefits Research arrives as the...

As February begins, the United States stock markets have shown strong performance, with major indices like the Dow Jones Industrial Average and S&P 500 experiencing significant gains. This positive momentum in the market presents an opportunity to explore stocks that may be undervalued, potentially trading below their estimated intrinsic value. Identifying such stocks requires a keen understanding of current market conditions and economic indicators to evaluate their true potential amidst...